NCT07468656
SCLC Blood Collection Study
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Enrollment increased: 25 → 100 participants Show 5 more changesShow less
- Primary endpoint(s) modified
- Start date: Oct 2026 to Jan 2027
- Eligibility criteria expanded, about 34 words
- Trial arms changed: 0 → 2
- Study title revised
- Notable Start date: Jul 2026 to Oct 2026v3
- Notable Start date: May 2026 to Jul 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Arms and interventions
Participants receiving tarlatamab as part of their routine cancer care.
Participants receiving other systemic therapies as part of their routine cancer care. This category includes, but is not limited to: platinum-etoposide chemotherapy (with or without concurrent radiation), chemoimmunotherapy (e.g., carboplatin/etoposide/atezolizumab, platinum/etoposide/durvalumab), maintenance immunotherapy (e.g., atezolizumab, durvalumab), consolidation immunotherapy (e.g., durvalumab post-chemoradiation for limited stage), lurbinectedin, antibody-drug conjugates (e.g., ifinatamab deruxtecan, sacituzumab govitecan, or other ADCs), topotecan, and any other systemic agents used in the treatment of small cell lung cancer (SCLC).